Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock - Currency: USD

9.8  +0.31 (+3.27%)

After market: 10 +0.2 (+2.04%)

Fundamental Rating

3

CRVO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. CRVO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CRVO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRVO has reported negative net income.
In the past year CRVO has reported a negative cash flow from operations.
In the past 5 years CRVO always reported negative net income.
CRVO had a negative operating cash flow in each of the past 5 years.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CRVO's Return On Assets of -37.81% is in line compared to the rest of the industry. CRVO outperforms 58.98% of its industry peers.
With a decent Return On Equity value of -41.56%, CRVO is doing good in the industry, outperforming 69.72% of the companies in the same industry.
Industry RankSector Rank
ROA -37.81%
ROE -41.56%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

CRVO has more shares outstanding than it did 1 year ago.
CRVO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 10.81 indicates that CRVO is not in any danger for bankruptcy at the moment.
CRVO's Altman-Z score of 10.81 is amongst the best of the industry. CRVO outperforms 89.61% of its industry peers.
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.81
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 11.11 indicates that CRVO has no problem at all paying its short term obligations.
CRVO has a better Current ratio (11.11) than 83.63% of its industry peers.
CRVO has a Quick Ratio of 11.11. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
CRVO has a better Quick ratio (11.11) than 83.63% of its industry peers.
Industry RankSector Rank
Current Ratio 11.11
Quick Ratio 11.11
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.41% over the past year.
The Revenue has grown by 36.19% in the past year. This is a very strong growth!
EPS 1Y (TTM)9.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.53%
Revenue 1Y (TTM)36.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-13.19%

3.2 Future

Based on estimates for the next years, CRVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.41% on average per year.
CRVO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.43% yearly.
EPS Next Y0.89%
EPS Next 2Y2.21%
EPS Next 3Y7.9%
EPS Next 5Y9.41%
Revenue Next Year-37.41%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y13.43%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2028 2029 2030 2031 2032 200M 400M 600M 800M
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.21%
EPS Next 3Y7.9%

More info and screens

0

5. Dividend

5.1 Amount

CRVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERVOMED INC

NASDAQ:CRVO (4/17/2025, 8:10:59 PM)

After market: 10 +0.2 (+2.04%)

9.8

+0.31 (+3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners18.17%
Inst Owner Change0%
Ins Owners26.36%
Ins Owner Change0%
Market Cap85.26M
Analysts80
Price Target16.15 (64.8%)
Short Float %16.91%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.61%
Min EPS beat(2)-30.72%
Max EPS beat(2)-24.49%
EPS beat(4)1
Avg EPS beat(4)-11.2%
Min EPS beat(4)-30.72%
Max EPS beat(4)13.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.33%
Min Revenue beat(2)-37.98%
Max Revenue beat(2)21.32%
Revenue beat(4)3
Avg Revenue beat(4)25.09%
Min Revenue beat(4)-37.98%
Max Revenue beat(4)70.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.81%
PT rev (3m)-33.1%
EPS NQ rev (1m)-23.35%
EPS NQ rev (3m)-15.51%
EPS NY rev (1m)-49.42%
EPS NY rev (3m)-38.35%
Revenue NQ rev (1m)25.79%
Revenue NQ rev (3m)11.94%
Revenue NY rev (1m)13.01%
Revenue NY rev (3m)12.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.76
P/FCF N/A
P/OCF N/A
P/B 2.17
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-2.03
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS1.12
BVpS4.51
TBVpS4.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.81%
ROE -41.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.11
Quick Ratio 11.11
Altman-Z 10.81
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.53%
EPS Next Y0.89%
EPS Next 2Y2.21%
EPS Next 3Y7.9%
EPS Next 5Y9.41%
Revenue 1Y (TTM)36.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-13.19%
Revenue Next Year-37.41%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y13.43%
EBIT growth 1Y-159.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.26%
EBIT Next 3Y-48.65%
EBIT Next 5Y-23.9%
FCF growth 1Y-121.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.89%
OCF growth 3YN/A
OCF growth 5YN/A